HERON THERAPEUTICS, INC. /DE/ Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
HERON THERAPEUTICS, INC. /DE/ (HRTX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.98 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.98M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.32M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $15.41M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $23.99M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $3.98M 10-K · filed 2026-02-26 |
| 2024-12-31 | $5.32M 10-K · filed 2026-02-26 |
| 2023-12-31 | $15.41M 10-K · filed 2025-02-27 |
| 2022-12-31 | $23.99M 10-K · filed 2024-03-12 |
| 2021-12-31 | $23.34M 10-K · filed 2023-03-29 |
| 2020-12-31 | $20.21M 10-K · filed 2022-02-28 |
| 2019-12-31 | $15.63M 10-K · filed 2021-02-24 |
| 2018-12-31 | $11.90M 10-K · filed 2020-03-02 |
| 2017-12-31 | $8.63M 10-K · filed 2019-02-22 |
| 2016-12-31 | $10.27M 10-K · filed 2018-02-27 |
| 2015-12-31 | $6.73M 10-K · filed 2017-02-23 |
| 2014-12-31 | $5.13M 10-K · filed 2016-02-19 |
| 2013-12-31 | $4.12M 10-K · filed 2015-03-13 |
| 2012-12-31 | $2.60M 10-K · filed 2014-03-07 |
| 2011-12-31 | $600.00K 10-K · filed 2014-03-07 |
| 2010-12-31 | $900.00K 10-K · filed 2013-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |